Increased activity of the sympathetic nervous system and the possibilities for therapeutic influence

Czech version

Authors: M. Souček; J. Nevrlka; I. Řiháček; P. Fráňa; M. Plachý
Authors‘ workplace: II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
Published in: Vnitř Lék 2007; 53(5): 554-559
Category:

Overview

Breakdown in the function of the autonomic nervous system (ANS) due to chronic stress is very probably one of the main pathophysiological mechanisms in the onset and development of essential hypertension, especially in younger hypertonic patients. The degree of dysfunction can be assessed by means of simple tests such as measurement of resting heart rate. Betablockers are the most effective group for chronic treatment of excessive activity of the sympathetic nervous system.

Key words:
chronic stress – autonomic nervous system – essential hypertension – heart rate – treatment

Sources

1. Kára T, Souček M. Autonomní nervový systém. In: Souček M, Kára T et al. Klinická patofyziologie hypertenze. Praha: Grada Publishing, 2002: 37-100.

2. Pickering TG. The effects of enviromental and lifestyle factors on blood pressure and the intermediary role of the sympathetic nervous systém. J Hum Hypertens 1997; 11 (Suppl 1): S9-S18.

3. Fišer B. Škodlivý účinek zvýšené sympatické aktivity u arteriální hypertenze. Cor Vasa 1999; 41: 241-246.

4. Rosolová H. Úloha sympatické nervové aktivity u esenciální arteriální hypertenze. Cor Vasa 1998; 40: 273-275.

5. Palatini P, Casiglia E, Pauletto P et al. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with micture analysis in three populations. Hypertension 1997; 30: 1267-1273.

6. Julius S Interaction between renin and the autonomic nervous system in hypertension. Am Heart J 1988; 116: 611-616.

7. Julius S, Majahalme S. The changing face of sympathetic overactivity in hypertension. Ann Med 2000; 6: 365-370.

8. Palatini P, Julius S. Heart rate and the cardiovascular risc. J Hypertens 1997; 15: 1-15.

9. Gillman MW, Kannel WB, Belanger A et al. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 1993; 125: 1148-1154.

10. Morcet JF, Safar M, Thomas F et al. Associations between heart rate and other risk factors in a large French population. J Hypertens 1999; 17: 1671-1676.

11. Levy RL, Hillman CC, Stroud WD et al. Transient hypertension: its significance in terms of later development of sustained hypertension and cardiovascular-renal diseases. JAMA 1944; 126: 829-833.

12. Widimsky J, Fejfarova MH, Fejfar Z. Changes of cardiac output in hypertensive disease. Cardiologia 1957; 31: 381-389.

13. Zuanetti G, Mantini L, Hernández-Bernal F. Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction: insight from the GISSI-2 study. Eur Heart J 1998; (Suppl F): 19-26.

14. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998; 19 (Suppl F): 14-18.

15. Palatini P, Julius S Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997; 11 (Suppl. 1): S19-S27.

16. Mangoni AA, Mircoli L, Giannattasio C et al. Heart rate-dependence of arterial distensibility in vivo. J Hypertens 1996; 14: 897-901.

17. Kaplan J, Manuck SB, Clarkson TB. The influence of heart rate on coronary artery atheroslerosis. J Cardiovasc Pharmacol 1987; 10 (2 Suppl): S100-S102.

18. Schmidt-Nielsen K Animal physiology: adaptation and enviroment. New York: Cambridge University Press, 1975: 133.

19. Nishime EO, Cole CR, Blackstone EH et al. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA 2000; 284: 1392-1398.

20. Placheta Z, Sieglová J, Štejfa M et al. Zátěžová diagnostika v ambulantní a klinické praxi. Praha: Grada Publishing, 1999.

21. Cífková R, Horký K, Widimský J st et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2004; 50: 709-722.

22. Prevence kardiovaskulárních onemocnění v dospělém věku - Společné doporučení českých odborných společností. Vnitř Lék 2005; 51: 3-15.

23. Widimský J Betablokátory. In: Souček M, Kára T et al. Klinická patofyziologie hypertenze. Praha: Grada Publishing, 2002: 572-580.

24. Janoušek S. Beta-blokátory v klinické praxi. Causa Subita 2003; 6: 461-465.

25. Vítovec J, Špinar J. Farmakoterapie kardiovaskulárních onemocnění. 2. ed. Praha: Grada Publishing 2004: 53-68.

26. Benetos A, Rudnichi A, Thomas F et al. HTA - fréquence cardiaque et risque cardiovasculaire. Arch Mal Coeur Vaiss 1993; (Suppl 11): 1371-1376.